Back

Efficacy and safety of prolonged rivaroxaban treatment for high-bleeding risk cancer patients with acute low-risk pulmonary embolism: a post-hoc subgroup analysis of the ONCO PE trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary embolism: general Venous Thromboembolism ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Tomoyuki Nagai

Kyoto Prefectural University of Medicine, Kyoto (Japan)

6 More presentations in this session

Presentation thumbnail
Gender disparities in high-risk pulmonary embolism: a nationwide analysis of management strategies and clinical outcomes
Doctor A. Folman (Hadera, IL)
Abstract Slides Video
Presentation thumbnail
Pandemic-era shifts in acute pulmonary embolism outcomes: national inpatient sample analysis of mortality and resource utilization (2016-2021)
Doctor M. Gatuz (Candon City, PH)
Abstract Slides Video
Presentation thumbnail
A meta-analysis of catheter-directed thrombolysis versus standard anticoagulation among patients with intermediate high risk pulmonary embolism
Doctor M. Apistar (Cebu, PH)
Abstract Slides Video
Presentation thumbnail
Burden and long-term impact of pulmonary embolism on health-related quality of life: a matched cohort study
Mr I. Farmakis (Munich, DE)
Abstract Slides Video
Presentation thumbnail
High-sensitivity troponin-t concentrations and early risk of myocardial infarction in patients with acute pulmonary embolism
Doctor J. Frary (Hellerup, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary embolism: general

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of long-term edoxaban treatment for low body weight cancer patients with isolated distal deep vein thrombosis: a post-hoc subgroup analysis of the ONCO DVT study
thumbnail
Congress Presentation
Impact of anemia on clinical outcomes of active cancer patients with low-risk pulmonary embolism receiving rivaroxaban: insight from the ONCO PE trial
thumbnail
Congress Presentation
Efficacy and safety of prolonged edoxaban treatment for gastrointestinal cancer patients with isolated distal deep vein thrombosis: insight from the ONCO DVT study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources